Stefani Spranger

Stefani Spranger

Howard S. and Linda B. Stern Career Development Professor; Intramural Faculty, Koch Institute

Stefani Spranger studies how the body’s immune system interacts with growing tumors to harness the immune response to fight cancer.





Paul Thompson



Assistant Phone


  • PhD, 2011, Ludwig-Maximilian University Munich/Helmholtz-Zentrum Munich
  • MSc, Biology, 2008, Ludwig-Maximilian University Munich/Helmholtz-Zentrum Munich
  • BSc, Biology, 2005, Ludwig-Maximilian University Munich/Helmholtz-Zentrum Munich

Research Summary

We examine the interaction between cancer and immune cells. Using tumor mouse models designed to mimic tumor progression in humans, we investigate the co-evolution of the anti-tumor immune response and cancer. Understanding the interplay between tumor cells and immune cells will help develop and improve effective cancer immunotherapies.


  • Forbeck Fellow, 2015

Recent Publications

  1. Once upon a prime: DCs shape cancer immunity. Zagorulya, M, Spranger, S. 2022. Trends Cancer , .
    doi: 10.1016/j.trecan.2022.10.006PMID:36357313
  2. Mesenchymal and adrenergic cell lineage states in neuroblastoma possess distinct immunogenic phenotypes. Sengupta, S, Das, S, Crespo, AC, Cornel, AM, Patel, AG, Mahadevan, NR, Campisi, M, Ali, AK, Sharma, B, Rowe, JH et al.. 2022. Nat Cancer 3, 1228-1246.
    doi: 10.1038/s43018-022-00427-5PMID:36138189
  3. Alum-anchored intratumoral retention improves the tolerability and antitumor efficacy of type I interferon therapies. Lutz, EA, Agarwal, Y, Momin, N, Cowles, SC, Palmeri, JR, Duong, E, Hornet, V, Sheen, A, Lax, BM, Rothschilds, AM et al.. 2022. Proc Natl Acad Sci U S A 119, e2205983119.
    doi: 10.1073/pnas.2205983119PMID:36037341
  4. Dendritic cell-mediated cross presentation of tumor-derived peptides is biased against plasma membrane proteins. Fessenden, TB, Stopfer, LE, Chatterjee, F, Zulueta, J, Mesfin, J, Cordero Dumit, T, Reijers, I, Hoefsmit, EP, Blank, C, White, F et al.. 2022. J Immunother Cancer 10, .
    doi: 10.1136/jitc-2021-004159PMID:35820727
  5. Deciphering the immunopeptidome in vivo reveals new tumour antigens. Jaeger, AM, Stopfer, LE, Ahn, R, Sanders, EA, Sandel, DA, Freed-Pastor, WA, Rideout, WM 3rd, Naranjo, S, Fessenden, T, Nguyen, KB et al.. 2022. Nature 607, 149-155.
    doi: 10.1038/s41586-022-04839-2PMID:35705813
  6. Reprogramming NK cells and macrophages via combined antibody and cytokine therapy primes tumors for elimination by checkpoint blockade. Wang, C, Cui, A, Bukenya, M, Aung, A, Pradhan, D, Whittaker, CA, Agarwal, Y, Thomas, A, Liang, S, Amlashi, P et al.. 2021. Cell Rep 37, 110021.
    doi: 10.1016/j.celrep.2021.110021PMID:34818534
  7. Type I interferon activates MHC class I-dressed CD11b+ conventional dendritic cells to promote protective anti-tumor CD8+ T cell immunity. Duong, E, Fessenden, TB, Lutz, E, Dinter, T, Yim, L, Blatt, S, Bhutkar, A, Wittrup, KD, Spranger, S. 2022. Immunity 55, 308-323.e9.
    doi: 10.1016/j.immuni.2021.10.020PMID:34800368
  8. Lack of CD8+ T cell effector differentiation during priming mediates checkpoint blockade resistance in non-small cell lung cancer. Horton, BL, Morgan, DM, Momin, N, Zagorulya, M, Torres-Mejia, E, Bhandarkar, V, Wittrup, KD, Love, JC, Spranger, S. 2021. Sci Immunol 6, eabi8800.
    doi: 10.1126/sciimmunol.abi8800PMID:34714687
  9. Immunogenomic determinants of tumor microenvironment correlate with superior survival in high-risk neuroblastoma. Bao, R, Spranger, S, Hernandez, K, Zha, Y, Pytel, P, Luke, JJ, Gajewski, TF, Volchenboum, SL, Cohn, SL, Desai, AV et al.. 2021. J Immunother Cancer 9, .
    doi: 10.1136/jitc-2021-002417PMID:34272305
  10. Increased demand for NAD+ relative to ATP drives aerobic glycolysis. Luengo, A, Li, Z, Gui, DY, Sullivan, LB, Zagorulya, M, Do, BT, Ferreira, R, Naamati, A, Ali, A, Lewis, CA et al.. 2021. Mol Cell 81, 691-707.e6.
    doi: 10.1016/j.molcel.2020.12.012PMID:33382985
More Publications



Photo credit: Kelsey Montgomery